[Sustained serum 25-hydroxyvitamin D concentrations for one year with cholecalciferol supplementation improves glycaemic control and slows the decline of residual β cell function in children with type 1 diabetes]
Panjiyar RP, Dayal D, Attri SV, Sachdeva N, Sharma R, Bhalla AK
Pediatric endocrinology, diabetes, and metabolism · 22 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2018-01-01 · Pediatr Endocrinol Diabetes Metab · vol. 24 · número 3 · págs. 111–117
- Citado
- 38 citas · más que el 87% de estudios similares · 2.1× el promedio de su campo
- Referencias
- 31 trabajos
- Acceso
- Acceso abierto (publicación gratuita) · CC-BY-NC-SA
- Áreas de investigación
- Vitamin D Research Studies · Diabetes and associated disorders · Celiac Disease Research and Management
- Palabras clave
- Cholecalciferol, Vitamin D and neurology, Type 2 diabetes, Internal medicine, Endocrinology, Medicine, Residual, Diabetes mellitus, Mathematics
- MeSH
- humans, diabetes mellitus, type 1, vitamin d deficiency, cholecalciferol, vitamin d, dietary supplements, child, female, male
6 autores
- Ram Prakash Panjiyar🇮🇳Post Graduate Institute of Medical Education and Research
- Devi Dayal🇮🇳 · autor de correspondenciaPost Graduate Institute of Medical Education and Research
- Savita Verma Attri🇮🇳Post Graduate Institute of Medical Education and Research
- Naresh Kumar Sachdeva🇮🇳Post Graduate Institute of Medical Education and Research
- Romesh Sharma🇮🇳Post Graduate Institute of Medical Education and Research
- Anil Kumar Bhalla🇮🇳Post Graduate Institute of Medical Education and Research
Resumen
El texto original del estudio, en el idioma en que se publicó.
Introduction
Studies using vitamin D for preservation of residual b-cell function (RBCF) and improvement of glycaemic control in type 1 diabetes (T1D) have shown inconsistent results. The possible causes of the discrepancies in the results are related to the dosage, type, and duration of vitamin D supplementation, C-peptide concentration at entry into the study, and the influence of glycaemic control on RBCF during supplementation.
Aim of the study
To evaluate the effect of cholecalciferol supplementation on RBCF and glycaemic control in children with T1D.
Material and methods
Forty-two children aged 6-12 years and within 1-2 years of diagnosis of T1D received cholecalciferol 3000 IU/day for one year (Group A). Thirty patients were recruited as controls (Group B). The mean changes in stimulated C-peptide levels, HbA1c, fasting blood glucose (FBG), mean blood glucose (MBG), and mean total daily insulin (TDI) dose from baseline to the study endpoint were calculated.
Results
Children in Group A showed lower mean FBG, MBG, HbA1c, and lesser TDI as compared to Group B at all follow-up visits. However, the differences in these parameters between the two groups reached statistical significance towards the study endpoint. Within group A, the decline in C-peptide levels from baseline to the endpoint was minor (-0.13 ±0.11, p-value = 0.16) as compared to a substantial decline in Group B (-0.41 ±0.07, p-value = 0.00). Comparison of the mean decrease in stimulated C-peptide levels from baseline to the endpoint between the two groups was also statistically significant (-0.13 ±0.11 vs. -0.41 ±0.07, p-value = 0.00). The mean decrease in FBG and MBG in Group A were greater, whereas the comparison of the mean decrease in HbA1c between the groups reached statistical significance at the study endpoint (p-value = 0.04). The decrease in the TDI was, however, similar in the two groups (p-value = 0.10).
Conclusions
Sustained serum 25-(OH)D concentrations with cholecalciferol supplementation for one year improves metabolic control and slows the decline of RBCF in children with T1D. Larger studies with longer duration and cholecalciferol dosage stratification are suggested.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.